Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | OXTR | P30559 | 2/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069133 | 0.83 | CHRM4 (0.49) | CHRM4HRH3OXTRAVPR1APIK3CD | |
| SCHEMBL20069570 | 0.82 | CHRM4 (0.53) | CHRM4HRH3OXTRAVPR1A | |
| SCHEMBL20147449 | 0.79 | HRH3 (0.47) | CHRM4HRH3OXTRAVPR1A | |
| SCHEMBL22857006 | 0.79 | CHRM4 (0.46) | CHRM4OXTRAVPR1APIK3CDPIK3CA | |
| SCHEMBL20137749 | 0.77 | PIK3CD (0.52) | CHRM4OXTRAVPR1APIK3CDPIK3CA | |
| SCHEMBL21651956 | 0.77 | HRH3 (0.53) | CHRM4HRH3PIK3CDESR1 | |
| SCHEMBL20137750 | 0.77 | PIK3CD (0.52) | CHRM4OXTRAVPR1APIK3CDPIK3CA | |
| SCHEMBL18822846 | 0.77 | HRH3 (0.56) | CHRM4HRH3 | |
| SCHEMBL4348402 | 0.76 | HRH3 (0.57) | HRH3ESR1PARP1 | |
| SCHEMBL20147423 | 0.76 | HRH3 (0.53) | CHRM4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CHRM4 2166/4885HRH3 1000/4885OXTR 3773/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRM4 2166/4885HRH3 1000/4885OXTR 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.